Reuters logo
BRIEF-Delmar Pharmaceuticals provides VAL-083 updates from ongoing American Association For Cancer Research annual meeting
April 5, 2017 / 1:04 PM / 6 months ago

BRIEF-Delmar Pharmaceuticals provides VAL-083 updates from ongoing American Association For Cancer Research annual meeting

April 5 (Reuters) - Delmar Pharmaceuticals Inc:

* Delmar pharmaceuticals provides val-083 updates from the ongoing American Association For Cancer Research (AACR) annual meeting

* Delmar Pharmaceuticals Inc - VAL-083 is active in cells with t790m and KRAS mutations indicating that agent can overcome TKI-resistance

* Delmar Pharma- poster demonstrates that val-083 has differentiated moa with a dual signaling pathway to cause permanent DNA damage in NSCLC cell lines Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below